Does screening for gestational diabetes mellitus make a difference?
Mathew Sermer
From the Department of
Obstetrics and Maternal-Fetal Medicine, Mount Sinai Hospital, Toronto, Ont.
Correspondence to: Dr.
Mathew Sermer, Department of Obstetrics and Maternal-Fetal Medicine, Mount Sinai
Hospital, 1207-600 University Ave., Toronto ON M5G 1X5; fax 416 586-4494;
msermer@mtsinai.on.ca
Ever since the introduction of the concept of gestational diabetes
mellitus, there has been controversy about the importance ofthis
condition and the appropriateness of screening for it.Societies and
associations such as the American College of Obstetriciansand
Gynecologists,1 the American Diabetes
Association (ADA),2the Canadian Diabetes
Association3 and the Fourth InternationalWorkshop-Conference on Gestational Diabetes Mellitus4
have recommendedeither universal or selective screening. These
recommendationsare based on the premise that identification and
treatment ofgestational diabetes will avert some of the adverse
outcomesthat have been associated with this condition, such as
pregnancy-induced hypertension, macrosomia (potentially associated
withfetal birth trauma), perinatal mortality and neonatal metabolicdisorders.5,6,7,8,9
Other bodies, such as the Canadian TaskForce on the Periodic Health
Examination10 and the Society of
Obstetricians and Gynaecologists of Canada,11
have taken a morecautious approach, noting that there is
insufficient scientificdata to suggest that identification and
treatment of gestationaldiabetes result in better maternal and
neonatal outcomes. Indeed,there is evidence that identification of
gestational diabetesmay result in unfavourable maternal outcomes.12
Hunter and Keirse,13in their contribution to
Effective Care in Pregnancy and Childbirth,concluded that
"except for research purposes all forms of glucosetolerance testing
should be stopped." Thus, it is importantthat studies be conducted
to determine whether identificationand treatment of gestational
diabetes is associated with improvementin maternal and neonatal
outcomes.
In this issue of CMAJ (page 403), Christian Ouzilleau and colleagues14report their retrospective study of 300 pregnant women who had
abnormal results on screening with a randomly administered 50-g
glucose load and who subsequently underwent a follow-up 3-hour,75-g
oral glucose tolerance test (OGTT). These women receivedminimal or
no therapeutic interventions. They were comparedwith a group of 300
pregnant women whose results on the initialscreening were normal.
The incidence of macrosomia was similarin the 2 groups.
The authors went on to look at the correlation between birth
weight and 3 separate sets of plasma glucose values: on screening(1
hour after a 50-g glucose load), while fasting and 2 hoursafter a
75-g load. In each of these 3 analyses, progressivelyincreasing
plasma glucose values were associated with a progressiveincrease in
birth weight, although the correlation was weakin each case.
Box 1.
The authors also performed multiple regression analysis to seeif
plasma glucose values while fasting and 2 hours after the75-g
glucose load remained independent predictors of birth weight.In both
cases, plasma glucose remained an independent predictor,but the
correlation was even weaker than in the initial analyses.The
multiple regression analysis also showed that prepregnancyweight,
weight gain during pregnancy and parity had a significantpositive
association with birth weight. Conversely, smokinghad a significant
but negative correlation with birth weight.Smoking, prepregnancy
weight, weight gain during pregnancy andparity had higher
correlations with birth weight than eitherfasting plasma glucose or
plasma glucose 2 hours after a 75-gload. These results confirm the
work of others, demonstratingthat factors other than gestational
diabetes are often associatedwith an increased rate of macrosomia.15
The ability of plasma glucose (on screening with a 50-g load,
while fasting and 2 hours after a 75-g load) to predict birthweight
at or above the 90% percentile was investigated by analysisof
receiver operating characteristic curves. According to Ouzilleauand
colleagues, the predictive value of these 3 plasma glucosevariables
was "mediocre" and demonstrated "modest risk stratification
performance."
The paper does not mention the proportion of patients who were
actually diagnosed with gestational diabetes at the time oftheir
pregnancies. It would appear that the proportion was lessthan 12.7%
or 13.3% (the proportions estimated retrospectivelyon the basis of
ADA criteria, as shown in Table 2 of the paper),given that the
diagnostic thresholds used by the institutionwhere the women
underwent screening (which were based on NationalDiabetes Data Group
criteria16) were higher than the ADA
thresholds.Therefore, it appears that about 90% of the study
populationhad no evidence of gestational diabetes and, for that
reason,a high rate of macrosomia should not have been anticipated.Thus, in their conclusions, the investigators are running a
risk of type II error.
The results of this carefully conducted study suggest that screeningfor gestational diabetes in an effort to prevent macrosomiamay
be unwarranted. This conclusion, however, depends entirelyon the
authors' assumption that the women identified with gestational
diabetes did not undergo any major interventions to lower their
glucose intolerance. This may or may not be the case. Thereis
evidence that when patients are identified as having gestational
diabetes, they or their physicians may alter their behaviour,which
could modify pregnancy outcome.12 For this
reason, onemust be cautious in interpreting outcomes in this
unblindedstudy, even though only minimal intervention was offered.
Theresearchers went to great lengths to obtain all of the pertinentinformation, but because the study was retrospective, the managementprotocol was not standardized, and many actions, interventions
or other confounding variables could have been missed. The results
should be considered in that light.
The authors did show that progressively increasing glucose values
were associated with increasing rate of macrosomia in this predominantlynondiabetic population. The association was thought to be weak
and became weaker once other macrosomia-related factors wereincluded
in the multivariate analysis. This finding correspondsto the results
of the Toronto Tri-Hospital Gestational DiabetesProject.17
This study underscores the controversy at the heart of the debate
over the importance, or even the existence, of gestational diabetes.
Some physicians in Canada do not believe that this conditionexists,
and others feel that its importance is so low that screeningis not
justified.11 Many researchers, in studies like
this one,are trying to shed light on this subject,9,17,18
but the controversywill only end once a robust, randomized,
double-blind trialis conducted to demonstrate whether identification
and managementof gestational diabetes is associated with significant
improvementin neonatal or maternal outcome. Unfortunately, no such
studyis yet under way.
While waiting for the results of such a trial, it would be reasonableto follow the SOGC guidelines published in November 200211
(seeBox 1).
ACOG Practice Bulletin. Clinical management guidelines for
obstetrician-gynecologists. Number 30, September 2001 (replaces Technical
Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol
2001;98: 52538.[Medline]
American Diabetes Association. Gestational diabetes mellitus.
Diabetes Care 1998; 22(Suppl 1):S74-6.
Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et
al. 1998 clinical practice guidelines for the management of diabetes in
Canada. CMAJ 1998;159(8 Suppl):S1-29.
Metzger BE, Coustan DR. Summary and recommendations of the
Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The
Organizing Committee. Diabetes Care 1998;21(Suppl 2):B1617.
O'Sullivan JB, Charles D, Mahan CM, Dandrow RV. Gestational
diabetes and perinatal mortality rate. Am J Obstet Gynecol
1973;116:901-4.[Medline]
Pettit DJ, Knowler WX, Baird HR, Bennett PH. Gestational
diabetes: infant and maternal complications of pregnancy in relation to third
trimester glucose tolerance in the Pima Indians. Diabetes Care
1980;3:458-64.[Abstract]
Ginsberg NA, Moisidis C. How to predict recurrent shoulder
dystocia. Am J Obstet Gynecol 2001;184:1427-9.[Medline]
Langer O, Rodriguez DA, Xenakis EMJ, McFarland MB, Berkus MD,
Arrendando F. Intensified versus conventional management of gestational
diabetes. Am J Obstet Gynecol 1994;170:1036-47.[Medline]
Periodic health examination, 1992 update: 1. Screening for
gestational diabetes mellitus. Canadian Task Force on the Periodic Health
Examination. CMAJ 1992;147(4):43543.[Medline]
Berger H, Crane J, Farine D. Screening for gestational diabetes
mellitus. J Obstet Gynaecol Can 2002;24(11):894-903.
[Medline]
Naylor CD, Sermer M, Chen E, Sykora K. Cesarean delivery in
relationship to birth weight and gestational glucose tolerance. JAMA
1966;275:1165-70.
Hunter DJS, Keirse MJNC. Gestational diabetes. In: Chalmers I,
editor. Effective care in pregnancy and childbirth. New York: Oxford
University Press; 1989. p. 403-10.
Ouzilleau C, Roy MA, Leblanc L, Carpentier A, Maheux P. An
observational study comparing 2-hour 75-g oral glucose tolerance with fasting
plasma glucose in pregnant women: both poorly predictive of birth weight.
CMAJ 2003;168(4):403-9.[Abstract/Free
Full Text]
Spellacy WN, Miller S, Winegar A, Peterson PQ. Macrosomia-maternal
characteristics and infant complications. Obstet Gynecol
1985;66:158-61.[Medline]
National Diabetes Data Group. Classification and diagnosis of
diabetes mellitus and other categories of glucose intolerance. Diabetes
1979;28(12):1039-57.[Medline]
Sermer M, Naylor CD, Gare DJ, Kenshole AB, Ritchie JWK, Farine
D, et al. Impact of increasing carbohydrate intolerance on maternal-fetal
outcomes in 3637 women without gestational diabetes. Am J Obstet Gynecol
1995;173:146-56.[Medline]
Garner P, Okun N, Keely E, Wells G, Perkins S, Sylvain J, et
al. A randomized controlled trial of strict glycemic control and tertiary
level obstetric care versus routine obstetric care in the management of
gestational diabetes: a pilot study. Am J Obstet Gynecol
1997;177:190-5.[Medline]
Related articles in eCMAJ:
An observational study comparing 2-hour 75-g oral glucose
tolerance with fasting plasma glucose in pregnant women: both poorly
predictive of birth weight
Christian Ouzilleau, Marie-Andrée Roy, Louiselle Leblanc, André Carpentier,
and Pierre Maheux
eCMAJ 2003 168: 403-409. [Abstract][Full Text]
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.
"A foolish faith in authority is the worst enemy of truth."
-- Albert Einstein, letter to a friend, 1901
"I know of no safe depository of the ultimate powers of the society but the people themselves, and if we think them not enlightened enough to exercise control with a wholesome discretion, the remedy is not to take it from them, but to inform their discretion by education."
-- Thomas Jefferson, letter to William C. Jarvis, September 28, 1820
"What's the point of vaccination if it doesn't protect you from the unvaccinated?"
-- Sandy Gottstein
"Who gets to decide what the greater good is and how many will be sacrificed to it?"